NASDAQ:OMCL - Omnicell Stock Price, Forecast & News

Omnicell's stock was trading at $77.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OMCL shares have decreased by 26.6% and is now trading at $56.85. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Omnicell.

Omnicell is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for Omnicell.

Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Thursday, February, 6th. The company reported $0.77 EPS for the quarter, missing the consensus estimate of $0.78 by $0.01. The company had revenue of $248.29 million for the quarter, compared to the consensus estimate of $243.69 million. Omnicell had a net margin of 6.84% and a return on equity of 11.76%. Omnicell's revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.70 EPS. View Omnicell's earnings history.

Omnicell updated its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of $2.96-3.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.00. The company issued revenue guidance of $1.00-1.02 billion, compared to the consensus revenue estimate of $991.00 million.

7 analysts have issued 12 month target prices for Omnicell's stock. Their forecasts range from $82.00 to $100.00. On average, they expect Omnicell's stock price to reach $89.29 in the next year. This suggests a possible upside of 57.1% from the stock's current price. View analysts' price targets for Omnicell.

Press coverage about OMCL stock has been trending extremely negative on Sunday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Omnicell earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutOmnicell.

Some companies that are related to Omnicell include Cerner (CERN), HMS (HMSY), Cortexyme (CRTX), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Vocera Communications (VCRA) and Computer Programs & Systems (CPSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Netflix (NFLX), Johnson & Johnson (JNJ), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD) and QUALCOMM (QCOM).

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Omnicell's stock is owned by a variety of retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (3.76%), Credit Suisse AG (3.51%), State Street Corp (2.88%), Eagle Asset Management Inc. (2.00%), Janus Henderson Group PLC (1.65%) and Geode Capital Management LLC (1.37%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View institutional ownership trends for Omnicell.

OMCL stock was sold by a variety of institutional investors in the last quarter, including Braun Stacey Associates Inc., Redwood Investments LLC, AQR Capital Management LLC, PNC Financial Services Group Inc., Kennedy Capital Management Inc., Charles Schwab Investment Management Inc., Falcon Point Capital LLC, and Westwood Holdings Group Inc.. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Joanne B Bauer, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, and Scott Peter Seidelmann. View insider buying and selling activity for Omnicell.

OMCL stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Marshall Wace LLP, Credit Suisse AG, Trillium Asset Management LLC, Bank of America Corp DE, WCM Investment Management LLC, Great West Life Assurance Co. Can, and Summit Creek Advisors LLC. View insider buying and selling activity for Omnicell.

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OMCL stock can currently be purchased for approximately $56.85.

Omnicell has a market capitalization of $2.41 billion and generates $897.03 million in revenue each year. The company earns $61.34 million in net income (profit) each year or $2.19 on an earnings per share basis. Omnicell employs 2,700 workers across the globe. View additional information about Omnicell.

The official website for Omnicell is http://www.omnicell.com/.

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]